Abstract
Biomarkers are used in the diagnosis, severity determination, and prognosis for patients with community-acquired pneumonia (CAP). Selected biomarkers may indicate a bacterial infection and need for antibiotic therapy (C-reactive protein, procalcitonin, soluble triggering receptor expressed on myeloid cells). Biomarkers can differentiate CAP patients who require hospital admission and severe CAP requiring intensive care unit admission. Biomarker-guided antibiotic therapy may limit antibiotic exposure without compromising outcome and thus improve antibiotic stewardship. The authors discuss the role of biomarkers in diagnosing, determining severity, defining the prognosis, and limiting antibiotic exposure in CAP and ventilator-associated pneumonia patients.
Original language | English (US) |
---|---|
Pages (from-to) | 691-701 |
Number of pages | 11 |
Journal | Clinics in Chest Medicine |
Volume | 39 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2018 |
Externally published | Yes |
Keywords
- Biomarkers
- Pneumonia diagnosis
- Procalcitonin
- Prognosis
- Scoring systems
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine